Prioritisation support creates better patient flow

Prolight Diagnostics is developing a Point-Of-Care (POC) system. POC means that diagnosis is made with a simple blood test with a mobile instrument. Testing takes place close to the patient, in patient care units, such as healthcentres and nursing homes.

Prioritisation support creates better patient flow

With the Prolight Diagnostics POC system, caregivers are able to focus on implementing the right treatment instead of spending critical time waiting for test results from the laboratory. The technology enables testing close to the patient and quick test results.

The ambition is for the test results to be available to doctors within 10 minutes. This means that the right treatment can be implemented quickly. Patients who need prompt and urgent healthcare can be prioritised at an early stage. This creates a better patient flow.

Based on the analysis, the doctor can quickly assess whether a patient, who may be in a healthcentre or emergency department, a nursing home, or an intensive care unit, has had, for example, a heart attack or not. By testing and analysing close to the patient, healthcare resources can save lives when they are prioritised for the right patient.

Prolight Diagnostics was founded in 1999 in Lund by Masoud Khayyami, PhD in Chemistry at Lund University. The goal was to develop a diagnostic test that could quickly determine if a patient had a heart attack, with a Point-Of-Care test. By measuring substances released from the heart into the blood during the acute myocardial infarction phase, rapid diagnosis can be determined. Since then, the development of general Point-Of-Care Testing (POCT) has progressed. Prolight Diagnostics has focused on developing a system for the biomarker Troponin, a marker that measures whether a patient has suffered a heart attack. We have received indications from the market to develop our POC platform to include more biomarkers. Our flexible testing system may, therefore, be modified to be able to measure markers in, for example, cancer, inflammation, stroke, etc. in the future.

Business model

The company’s aim is to create collaboration with one or more potential industrial players during the third stage of the development phase, or to explore the possibilities for licensing or divestment. In the case of a collaboration, revenue is expected to come from the sale of test cards (consumables) and instruments.

Unique innovation

We have developed the POC system with the first biomarker, highly sensitive Troponin. Through our new innovation, the blood sampling tube can be integrated directly into the automated process. The manual stages found in most methods on the market today, such as pipetting, centrifugation and dilution, can thereby be eliminated.

Our goal is to be able to offer a simple, flexible and automated analysis process.

Prioritisation support creates better patient flow